DIGICORE's primary objective is to improve cancer outcomes
through real-world research. In the short term, it will focus on developing a
programme for real-world outcomes research. This research uses the experiences of today's cancer patients across
different cancer centres to inform researchers about the benefits of various treatment options.
without sharing individual patient data.
They can identify the most effective treatments for different patient groups,
improving cancer care in areas like diagnostics, surgery, radiotherapy, and systemic treatments.
through academic and commercial trials.
They plan to collaborate with patient groups and other stakeholders to ensure patient-centred research.
Data privacy is a top priority for DIGICORE
Patients' data always remain under the control of their hospital teams
Personal data are never sent off site without
The use of data for research is carefully controlled by cancer experts and patient representatives.
DIGICORE is also working on advanced research methods to make research more efficient while protecting privacy.
DIGICORE promotes efficient digital research to enhance patient outcomes across various treatments and stages.
supporting both academic and commercial research.
with privacy controls and GDPR compliance.
Learn from cutting-edge peer institutions and secure funding to integrate your data for research.
Join the digital cancer research revolution.
We aim to solve difficult research problems by creating a large network of connected molecular-clinical data
for cancer research under hospital control.
Besides traditional observational studies, we focus on three main areas:
with pre-contracted networks with molecular data and strong clinical
phenotyping at every clinical decision point. This helps understand
the natural history and outcomes of rare subgroups.
including the natural experimentation that occurs during individual treatment decision-making,
especially for patients with unmet needs.
Case series studies have shown to secure reimbursement and extend innovative options to new patient groups.
by using Mendelian randomisation on somatic mutations compared to standard care.
By improving the evidence base on large panel tests and expanding clinical actionability,
we help partners minimize risk during launches and provide patients with broader
access to effective innovation and trials.
by investing in digital infrastructure.
Traditional trials and studies are all one-off and rely on high cost manual processes,
with high hidden set-up costs.
This is especially true in the era of precision oncology where every patient
is a rare patient from whom we can collectively learn for the benefit of future rare patients.
As the main funders of cancer care, you need reliable information on real-world practice and outcomes.
Trials might not reflect the complexities of real-world situations.
from different care systems.
We intend that DIGICORE studies become synonymous with high research
standards and excellence in European cancer research.